The first domestic targeted il-36r monoclonal antibody was administered to the first subject in New Zealand
According to the official account of WeChat, Shanghai, China's Limited by Share Ltd has announced that the HB0034 project, the first recombinant IL-36R monoclonal antibody against human IL-36R, has been completed in New Zealand. The phase ia clinical study conducted in New Zealand aims to evaluate the safety, tolerance, immunogenicity and pharmacokinetics of hb0034 in healthy subjects. Huaaotai biology is a subsidiary of Huahai pharmaceutical, a listed company.
This text is a result of machine translation.
Related companies：
Briefing Oct 20, 2023 06:03 PM
· Technology
China’s OpenAI Challenger Zhipu AI Secures Over CNY 2.5 Billion to Step Further on Large-Scale Model
In-depth
Technology
Insta360: Champion the Boldest, Craziest, Wildest of Ideas
The rise of VR camera in today's digital age has already changed the way we record and share our lives. Insta360 (Chinese: 影石), a Chinese tech company founded in 2015, has become a globally renowned intelligent imaging brand thanks to its innovative panoramic technology. Through independent research and continuous technological innovation, the company has met the imaging needs of consumers in different scenarios.
Dec 07, 2023 03:35 PM
Briefing Sep 18, 2023 07:40 PM
· Technology
4Paradigm Initiates IPO Today and Targets HKSE on September 28
Briefing Feb 23, 2023 10:59 AM
· Technology
Power Device Company Maplesemi Completes Series A+ Financing Round
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Nov 10, 2022 02:39 PM
Nov 08, 2022 08:32 AM
Technology
Winall Hi-Tech releases ESG report
Insisting on echnology-first actio.
Dec 06, 2023 03:31 PM
Insight
Technology
Consumer Electronics: ESG Emerging as a Hidden Highlight
In the face of the global consumer electronics industry in the cold, the future is more than relying on technological iteration and consumer upgrades, ESG and sustainable is providing new possibilities for the development of the industry.
Nov 30, 2023 10:11 PM
Insight
Briefing Aug 26, 2021 06:31 PM
· Healthcare
Huahai pharmaceutical: the net profit in the first half of the year was 516 million yuan, a year-on-year decrease of 10.84%
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth
Chinese Enterprises are Ready to Tell Stories of Green China at COP28
Dec 02, 2023 12:28 AM
Insight
In-depth